STOCK TITAN

[8-K] Trinity Capital Inc. 7.875% Notes due 2029 Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Intellia Therapeutics (NTLA) has filed a Form 4 reporting that Vice President & Chief Accounting Officer Michael P. Dube sold 2,503 shares of common stock on 07/02/2025 at $9.95 per share. The filing states this was a mandatory sell-to-cover transaction to satisfy tax-withholding obligations arising from the vesting of restricted stock units (RSUs) on 07/01/2025, rather than a discretionary sale. After the transaction, Dube continues to hold 57,137 shares directly. No derivative positions were reported.

The dollar value of the sale (≈ $25 k) is immaterial relative to Intellia’s market capitalization and daily trading volume, and the officer retains a meaningful equity stake. As such, investors are likely to view the disclosure as routine housekeeping with neutral implications for the stock’s fundamental outlook.

Intellia Therapeutics (NTLA) ha presentato un Modulo 4 segnalando che il Vicepresidente e Chief Accounting Officer Michael P. Dube ha venduto 2.503 azioni ordinarie il 02/07/2025 al prezzo di 9,95 $ per azione. La comunicazione specifica che si è trattato di una transazione obbligatoria di tipo sell-to-cover per adempiere agli obblighi fiscali derivanti dalla maturazione delle unità di azioni vincolate (RSU) il 01/07/2025, e non di una vendita discrezionale. Dopo l’operazione, Dube detiene direttamente ancora 57.137 azioni. Non sono state segnalate posizioni derivanti da strumenti finanziari derivati.

Il valore della vendita (circa 25.000 $) è irrilevante rispetto alla capitalizzazione di mercato di Intellia e al volume giornaliero di scambi, e il dirigente mantiene una partecipazione azionaria significativa. Pertanto, gli investitori probabilmente considereranno questa comunicazione come una normale attività amministrativa con implicazioni neutre per le prospettive fondamentali del titolo.

Intellia Therapeutics (NTLA) ha presentado un Formulario 4 informando que el Vicepresidente y Director de Contabilidad, Michael P. Dube, vendió 2,503 acciones ordinarias el 02/07/2025 a $9.95 por acción. El informe indica que esta fue una transacción obligatoria de tipo sell-to-cover para cubrir obligaciones fiscales derivadas del otorgamiento de unidades de acciones restringidas (RSU) el 01/07/2025, y no una venta discrecional. Tras la operación, Dube sigue poseyendo directamente 57,137 acciones. No se reportaron posiciones derivadas.

El valor en dólares de la venta (aproximadamente $25,000) es insignificante en relación con la capitalización de mercado de Intellia y el volumen diario de negociación, y el ejecutivo mantiene una participación accionaria significativa. Por ello, es probable que los inversores consideren la divulgación como un trámite rutinario con implicaciones neutras para las perspectivas fundamentales de la acción.

Intellia Therapeutics (NTLA)는 부사장 겸 최고회계책임자 Michael P. Dube가 2025년 7월 2일에 보통주 2,503주를 주당 $9.95에 매도했다고 Form 4를 제출했습니다. 제출서류에 따르면 이번 거래는 2025년 7월 1일 제한 주식 단위(RSU)의 권리 확정에 따른 세금 원천징수 의무를 충족하기 위한 의무적인 sell-to-cover 거래였으며, 임의 매도는 아니었습니다. 거래 후 Dube는 직접 57,137주를 계속 보유하고 있습니다. 파생상품 포지션은 보고되지 않았습니다.

매도 금액(약 2만 5천 달러)은 Intellia의 시가총액 및 일일 거래량에 비해 미미하며, 임원은 여전히 상당한 지분을 보유하고 있습니다. 따라서 투자자들은 이번 공시를 기본적인 주식 관리 절차로 보고, 주가의 근본적인 전망에 대해 중립적인 영향으로 받아들일 가능성이 높습니다.

Intellia Therapeutics (NTLA) a déposé un formulaire 4 indiquant que le vice-président et directeur comptable Michael P. Dube a vendu 2 503 actions ordinaires le 02/07/2025 au prix de 9,95 $ par action. Le dépôt précise qu’il s’agissait d’une opération obligatoire de type sell-to-cover destinée à couvrir les obligations fiscales liées à l’acquisition de unités d’actions restreintes (RSU) le 01/07/2025, et non d’une vente discrétionnaire. Après la transaction, M. Dube détient encore directement 57 137 actions. Aucune position dérivée n’a été signalée.

La valeur de la vente (environ 25 000 $) est négligeable par rapport à la capitalisation boursière d’Intellia et au volume quotidien d’échanges, et le dirigeant conserve une participation significative. Ainsi, les investisseurs considéreront probablement cette déclaration comme une formalité administrative avec des implications neutres sur les perspectives fondamentales de l’action.

Intellia Therapeutics (NTLA) hat ein Formular 4 eingereicht, in dem berichtet wird, dass der Vizepräsident und Chief Accounting Officer Michael P. Dube am 02.07.2025 2.503 Aktien der Stammaktien zu je 9,95 $ verkauft hat. Die Meldung gibt an, dass es sich um eine verpflichtende sell-to-cover-Transaktion handelte, um steuerliche Verpflichtungen infolge der Vesting von Restricted Stock Units (RSUs) am 01.07.2025 zu erfüllen, und nicht um einen freiwilligen Verkauf. Nach der Transaktion hält Dube weiterhin 57.137 Aktien direkt. Es wurden keine Derivatpositionen gemeldet.

Der Verkaufswert (ca. 25.000 $) ist im Verhältnis zur Marktkapitalisierung und dem täglichen Handelsvolumen von Intellia unerheblich, und der Manager behält eine bedeutende Aktienbeteiligung. Daher werden Investoren die Offenlegung wahrscheinlich als routinemäßige Formalität mit neutralen Auswirkungen auf die fundamentale Perspektive der Aktie ansehen.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine sell-to-cover; minimal financial impact.

The Form 4 reveals a small, non-volitional sale equal to roughly 4% of the officer’s holdings and an immaterial fraction of NTLA’s float. Because proceeds merely cover withholding taxes tied to RSU vesting, the transaction does not suggest a change in sentiment or insider confidence. Continued ownership of 57,137 shares aligns management incentives with shareholders. I classify the filing as neutral for valuation and trading purposes.

TL;DR: Compliance disclosure; governance posture unchanged.

The company has met Section 16 reporting requirements within two business days, indicating strong compliance practices. The explanatory note clarifies the compulsory nature of the sale, mitigating concerns about opportunistic trading. Insider alignment remains intact given the sizable residual stake. From a governance risk standpoint, the event is non-impactful.

Intellia Therapeutics (NTLA) ha presentato un Modulo 4 segnalando che il Vicepresidente e Chief Accounting Officer Michael P. Dube ha venduto 2.503 azioni ordinarie il 02/07/2025 al prezzo di 9,95 $ per azione. La comunicazione specifica che si è trattato di una transazione obbligatoria di tipo sell-to-cover per adempiere agli obblighi fiscali derivanti dalla maturazione delle unità di azioni vincolate (RSU) il 01/07/2025, e non di una vendita discrezionale. Dopo l’operazione, Dube detiene direttamente ancora 57.137 azioni. Non sono state segnalate posizioni derivanti da strumenti finanziari derivati.

Il valore della vendita (circa 25.000 $) è irrilevante rispetto alla capitalizzazione di mercato di Intellia e al volume giornaliero di scambi, e il dirigente mantiene una partecipazione azionaria significativa. Pertanto, gli investitori probabilmente considereranno questa comunicazione come una normale attività amministrativa con implicazioni neutre per le prospettive fondamentali del titolo.

Intellia Therapeutics (NTLA) ha presentado un Formulario 4 informando que el Vicepresidente y Director de Contabilidad, Michael P. Dube, vendió 2,503 acciones ordinarias el 02/07/2025 a $9.95 por acción. El informe indica que esta fue una transacción obligatoria de tipo sell-to-cover para cubrir obligaciones fiscales derivadas del otorgamiento de unidades de acciones restringidas (RSU) el 01/07/2025, y no una venta discrecional. Tras la operación, Dube sigue poseyendo directamente 57,137 acciones. No se reportaron posiciones derivadas.

El valor en dólares de la venta (aproximadamente $25,000) es insignificante en relación con la capitalización de mercado de Intellia y el volumen diario de negociación, y el ejecutivo mantiene una participación accionaria significativa. Por ello, es probable que los inversores consideren la divulgación como un trámite rutinario con implicaciones neutras para las perspectivas fundamentales de la acción.

Intellia Therapeutics (NTLA)는 부사장 겸 최고회계책임자 Michael P. Dube가 2025년 7월 2일에 보통주 2,503주를 주당 $9.95에 매도했다고 Form 4를 제출했습니다. 제출서류에 따르면 이번 거래는 2025년 7월 1일 제한 주식 단위(RSU)의 권리 확정에 따른 세금 원천징수 의무를 충족하기 위한 의무적인 sell-to-cover 거래였으며, 임의 매도는 아니었습니다. 거래 후 Dube는 직접 57,137주를 계속 보유하고 있습니다. 파생상품 포지션은 보고되지 않았습니다.

매도 금액(약 2만 5천 달러)은 Intellia의 시가총액 및 일일 거래량에 비해 미미하며, 임원은 여전히 상당한 지분을 보유하고 있습니다. 따라서 투자자들은 이번 공시를 기본적인 주식 관리 절차로 보고, 주가의 근본적인 전망에 대해 중립적인 영향으로 받아들일 가능성이 높습니다.

Intellia Therapeutics (NTLA) a déposé un formulaire 4 indiquant que le vice-président et directeur comptable Michael P. Dube a vendu 2 503 actions ordinaires le 02/07/2025 au prix de 9,95 $ par action. Le dépôt précise qu’il s’agissait d’une opération obligatoire de type sell-to-cover destinée à couvrir les obligations fiscales liées à l’acquisition de unités d’actions restreintes (RSU) le 01/07/2025, et non d’une vente discrétionnaire. Après la transaction, M. Dube détient encore directement 57 137 actions. Aucune position dérivée n’a été signalée.

La valeur de la vente (environ 25 000 $) est négligeable par rapport à la capitalisation boursière d’Intellia et au volume quotidien d’échanges, et le dirigeant conserve une participation significative. Ainsi, les investisseurs considéreront probablement cette déclaration comme une formalité administrative avec des implications neutres sur les perspectives fondamentales de l’action.

Intellia Therapeutics (NTLA) hat ein Formular 4 eingereicht, in dem berichtet wird, dass der Vizepräsident und Chief Accounting Officer Michael P. Dube am 02.07.2025 2.503 Aktien der Stammaktien zu je 9,95 $ verkauft hat. Die Meldung gibt an, dass es sich um eine verpflichtende sell-to-cover-Transaktion handelte, um steuerliche Verpflichtungen infolge der Vesting von Restricted Stock Units (RSUs) am 01.07.2025 zu erfüllen, und nicht um einen freiwilligen Verkauf. Nach der Transaktion hält Dube weiterhin 57.137 Aktien direkt. Es wurden keine Derivatpositionen gemeldet.

Der Verkaufswert (ca. 25.000 $) ist im Verhältnis zur Marktkapitalisierung und dem täglichen Handelsvolumen von Intellia unerheblich, und der Manager behält eine bedeutende Aktienbeteiligung. Daher werden Investoren die Offenlegung wahrscheinlich als routinemäßige Formalität mit neutralen Auswirkungen auf die fundamentale Perspektive der Aktie ansehen.

false 0001786108 0001786108 2025-07-03 2025-07-03 0001786108 TRIN:CommonStockParValue0.001PerShareMember 2025-07-03 2025-07-03 0001786108 TRIN:Sec7.875NotesDue2029Member 2025-07-03 2025-07-03 0001786108 TRIN:Sec7.875NotesDue2029aMember 2025-07-03 2025-07-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 3, 2025

 

 

 

TRINITY CAPITAL INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Maryland   001-39958   35-2670395
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

1 N. 1st Street

3rd Floor

Phoenix, Arizona

  85004
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (480) 374-5350

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   TRIN   Nasdaq Global Select Market
7.875% Notes Due 2029   TRINZ   Nasdaq Global Select Market
7.875% Notes Due 2029   TRINI   Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 1.01 – Entry into a Material Definitive Agreement

 

On July 3, 2025, Trinity Capital Inc. (the “Company”) and U.S. Bank Trust Company, National Association (the “Trustee”), entered into a seventh supplemental indenture (the “Seventh Supplemental Indenture”) to the indenture, dated as of January 16, 2020, between the Company and the Trustee (the “Base Indenture”; and together with the Seventh Supplemental Indenture, the “Indenture”), relating to the Company’s issuance of $125,000,000 aggregate principal amount of its 6.750% notes due 2030 (the “Notes”).

 

The Notes will mature on July 3, 2030, and may be redeemed in whole or in part at the Company’s option at any time prior to June 3, 2030 at par value plus a “make-whole” premium calculated in accordance with terms under the Indenture and at par on June 3, 2030 or thereafter. The Notes bear interest at a rate of 6.750% per year payable semi-annually on January 3 and July 3 of each year, commencing on January 3, 2026. The Notes are direct, general unsecured obligations of the Company that rank senior in right of payment to all of the Company’s existing and future indebtedness or other obligations that are expressly subordinated in right of payment to the Notes, rank pari passu with all existing and future unsecured unsubordinated indebtedness or other obligations issued by the Company, rank effectively junior to any of the Company’s secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness, and rank structurally junior to all existing and future indebtedness or other obligations (including trade payables) incurred by the Company’s subsidiaries, financing vehicles or similar facilities.

   

The Indenture contains certain covenants, including covenants requiring the Company to comply with the asset coverage requirements of Section 18(a)(1)(A) as modified by Section 61(a) of the Investment Company Act of 1940, as amended, or any successor provisions, but giving effect, in either case, to any exemptive relief granted to the Company by the Securities and Exchange Commission, and to provide financial information to the holders of the Notes and the Trustee if the Company should no longer be subject to the reporting requirements under the Securities Exchange Act of 1934, as amended. These covenants are subject to important limitations and exceptions that are described in the Indenture.

 

In addition, upon the occurrence of a “change of control repurchase event,” as defined in the Indenture, the Company will generally be required to make an offer to purchase the Notes at a price equal to 100% of the principal amount of such Notes plus accrued and unpaid interest to, but not including, the date of purchase.

 

The Notes were offered and sold in an offering registered under the Securities Act of 1933, as amended, pursuant to the Registration Statement on Form N-2 (File No. 333-275970) previously filed with the Securities and Exchange Commission, as supplemented by a preliminary prospectus supplement dated June 26, 2025, a final prospectus supplement dated June 26, 2025, and the pricing term sheet dated June 26, 2025. The transaction closed on July 3, 2025. The net proceeds to the Company were approximately $121.23 million, after deducting the underwriting discounts and estimated offering expenses. The Company intends to use the net proceeds to repay outstanding secured indebtedness under its credit agreement with KeyBank, National Association.

 

The foregoing descriptions of the Base Indenture, Seventh Supplemental Indenture and the Notes do not purport to be complete and are qualified in their entirety by reference to the full text of the Base Indenture, Seventh Supplemental Indenture and the form of global note representing the Notes, respectively, each filed as exhibits hereto and incorporated by reference herein.

 

1

 

 

Item 2.03 – Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant

 

The information set forth under Item 1.01 of this Form 8-K is incorporated herein by reference.

 

Item 9.01 – Financial Statements and Exhibits

 

(d) Exhibits:

 

Exhibit
Number
  Description
     
4.1   Indenture, dated as of January 16, 2020, by and between Trinity Capital Inc. and U.S. Bank Trust Company, National Association, as trustee (incorporated by reference to exhibit 4.3 to the Company’s Registration Statement on Form 10 filed on January 16, 2020).
     
4.2   Seventh Supplemental Indenture, dated as of July 3, 2025, between Trinity Capital Inc. and U.S. Bank Trust Company, National Association, as Trustee
     
4.3   Form of 6.750% Note Due 2030 (included as part of Exhibit 4.2)
     
5.1   Opinion of Dechert LLP
     
23.1   Consent of Dechert LLP (included as part of Exhibit 5.1)
     
104   Cover page interactive data file (formatted as Inline XBRL)

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  Trinity Capital Inc.
   
July 3, 2025 By: /s/ Kyle Brown
    Name:  Kyle Brown
    Title: Chief Executive Officer, President and Chief Investment Officer

 

3

 

FAQ

How many NTLA shares did Michael P. Dube sell on 07/02/2025?

He sold 2,503 common shares according to the Form 4 filing.

What price did the insider receive for the NTLA shares?

The reported sale price was $9.95 per share.

Why were the NTLA shares sold by the insider?

The sale was a mandatory sell-to-cover to pay taxes due on RSU vesting, not a discretionary trade.

How many NTLA shares does Michael P. Dube still own after the sale?

He continues to own 57,137 shares directly.

Does this Form 4 signal negative sentiment from Intellia management?

Given its tax-withholding purpose and small size, analysts view the transaction as neutral with no change in management outlook.
TRINITY CAPITAL 7 875 NTS

NASDAQ:TRINZ

TRINZ Rankings

TRINZ Latest News

TRINZ Latest SEC Filings

TRINZ Stock Data

4.67M
PHOENIX